Beijing Tide Pharmaceutical Co. Ltd. has described orydalmine derivatives reported to be useful for the treatment of pain, depression, and substance abuse and dependence.

Impact Therapeutics (Shanghai) Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Pfizer Inc. has divulged cyclin-dependent kinase 2 (CDK2), 4 (CDK4) and 6 (CDK6) inhibitors reported to be useful for the treatment of cancer.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have presented compounds reported to be useful for the treatment of gram-negative bacterial infections.

Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.

Ildong Pharmaceutical Co. Ltd. has described GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has patented potassium voltage-gated channel subfamily C member 1 (Kv3.1; KCNC1) activators reported to be useful for the treatment of neurological and psychiatric disorders.

Exelixis Inc. has presented ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

A Tisento Therapeutics Inc. patent describes new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, vascular dementia, ischemic stroke, Leigh syndrome, Pearson syndrome, creatine deficiency syndrome and Alpers syndrome, among others.